Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
Completed · Phase 2 · Has a placebo group
Conditions studied: Spinal Muscular Atrophy
In brief
This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
Key facts
- Study ID
- NCT00227266
- Run by
- University of Utah
- People needed
- 94
- Starts
- 2005-09-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2025-03-19
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Cohort 1
- Confirmed genetic diagnosis of 5q SMA
- SMA 2 or non-ambulatory SMA 3: all subjects must be able to sit independently for at least 3 seconds without support
- Age 2 to 8 years at time of enrollment
- Cohort 2
- Confirmed genetic diagnosis of 5q SMA
- SMA subjects (SMA types 2 or 3) who can stand independently without braces or other support for up to 2 seconds, or walk independently
- Age 3 to 17 years at time of study enrollment
You may not qualify if…
- Cohort 1
- Need for BiPAP support > 12 hours per day
- Spinal rod or fixation for scoliosis or anticipated need within six months of enrollment
- Inability to meet study visit requirements or cooperate reliably with functional testing
- Coexisting medical conditions that contraindicate travel, testing or study medications
- Use of medications or supplements which interfere with valproic acid or carnitine metabolism within 3 months of study enrollment.
- Current use of either VPA or carnitine. If study subject is taking VPA or carnitine then patient must go through a washout period of 12 weeks before enrollment into the study
- Body Mass Index > 90th % for age
- Cohort 2
- Spinal rod or fixation for scoliosis or anticipated need within six months of enrollment
- Inability to meet study visit requirements or cooperate with functional testing
- Transaminases, amylase or lipase > 3.0 x normal values, WBC < 3.0 or neutropenia < 1.0, platelets < 100 K, or hematocrit < 30 persisting over a 30 day period.
- Coexisting medical conditions that contraindicate travel, testing or study medications
- Use of medications or supplements which interfere with valproic acid or carnitine metabolism within 3 months of study enrollment.
- Current use of either VPA or carnitine. If study subject is taking VPA or carnitine then patient must be go through a washout period of 12 weeks before enrollment in the study.
- Body Mass Index > 90th % for age
- Pregnant women/girls, or those intending to try to become pregnant during the course of the study.
Where it is running
- Johns Hopkins University — Baltimore, Maryland, United States
- Children's Hospital of Michigan — Detroit, Michigan, United States
- Ohio State University — Columbus, Ohio, United States
- University of Utah/Primary Children's Medical Center — Salt Lake City, Utah, United States
- University of Wisconsin Children's Hospital — Madison, Wisconsin, United States
- Hospital Sainte-Justine — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.